Displaying drugs 13526 - 13550 of 15142 in total
Mazorelvimab
Investigational
Porgaviximab
Investigational
Cosfroviximab
Investigational
VAC-52150
Investigational
CY 1899
Investigational
Miromavimab
Investigational
West Nile immune globulin
Investigational
LJP-538
Investigational
Lenvervimab
Investigational
ACP-015
Investigational
SIG-001
SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer modified alginate spheres.
Investigational
CUR-1916
Investigational
RST-001
RST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channel rhodopsin-2 protein.
Investigational
GS030-DP
GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector. It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
Investigational
WVE-N531
Investigational
OCU-100
Investigational
AAV1-FS344
AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor. It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myositis.[L46742, L46747, L46752]
Investigational
Matched Description: … is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and …
SPL23-2
SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.
Investigational
QR-1123
QR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin (RHO) gene.
Investigational
AAV-dXIAP
AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.
Investigational
FOV 2501
Investigational
Recombinant human type VII collagen
Investigational
Exon 55 specific phosphorothioate oligonucleotide
Investigational
Human allogeneic bone marrow derived osteoblastic cells
Investigational
Recombinant human galactocerebrosidase
Investigational
Displaying drugs 13526 - 13550 of 15142 in total